Antihypertensive Effectiveness of Hiten (Perindopril) in Patients with Mild to Moderate Arterial Hypertension
Aim. To study antihypertensive efficacy and tolerability of the drug Hiten (perindopril) manufactured by «Aurobindo Pharma Limited», India, in patients with mild to moderate arterial hypertension. Methods. The study included 53 patients. The control of office blood pressure (BP) and heart rate, effectiveness of the therapy was made, we have recorded the cases of adverse reactions, performed ambulatory BP monitoring, the control of biochemical parameters of the blood serum, total blood count. Hiten at a dose of 4–8 mg 1 time a day was administered for 30 days. In cases when the target level of BP was not reached, if necessary, hydrochlorothiazide 12.5 mg 1 time per day was added. The total course of treatment for one patient was 6 months. The average age of the patients was 51.38 ± 1.40 years, body mass index — 29.50 ± 0.59 kg/m2.
Baseline level of average office systolic BP (SBP) and diasto-lic BP (DBP) in the whole group was 156.77 ± 0.66 mmHg and 95.19 ± 0.98 mmHg. Results. It was found that in patients with mild to moderate hypertension, the treatment by Hiten (perindopril) in a dose of 4–8 mg (alone or in combination with hydrochlorothiazide) provides a significant decrease in both office SBP — by 28.67 mmHg, DBP — by 14.57 mmHg, and average daily SBP — by 14.14 mmHg and DBP — by 7.55 mmHg, as well as lowers the indices of time and pressure. Target BP according to office measurements (< 140/90 mmHg) was achieved in 88 % of patients, according to ambulatory BP monitoring (< 130/80 mmHg) — in 78 % of cases. Withdrawal of the drug was in 3 patients (5.6 %). Conclusion. Results of the study indicate a high antihypertensive efficacy and good tolerability of therapy with Hiten (perindopril) — both as monotherapy and in combination with hydrochlorothiazide in patients with mild to moderate hypertension.
Full Text:PDF (Українська)
Малыхина А.И., Журавлева М.В., Стародубцев А.К., Рогачева О.А. Сравнительное изучение эффективности и переносимости оригинальных и генерических препаратов периндоприла // Лечащий врач. — 2013. — № 2. — С. 15-23.
Brugts J.J., Arima H., Remme W. et al. The incidence and clinical predictors of ACE-inhibitor induced dry cough by perindopril in 27,492 patients with vascular disease // Int. J. Cardiol. — 2014. — Vol. 20, 176(3). — P. 718-723.
DiNicolantonio J.J., O’Keefe J.H. Perindopril for improving cardiovascular events // Vasc. Health Risk Manag. — 2014. — Vol. 30, 10. — P. 539-548.
Qi L., Zhao S., Li H. et al. Efficacy comparison between 5 mg perindopril arginine salt and 4 mg perindopril tert-butylamine salt for patients with mild to moderate essential hypertension // ZhonghuaXinXue Guan Bing ZaZhi. — 2015. — Vol. 43(10). — P. 863-867.
Sindone A., Erlich J., Lee C. et al. Cardiovascular risk reduction in hypertension: angiotensin-converting enzyme inhibitors, angiotensin receptor blockers. Where are we up to? // Intern. Med. J. — 2016. — Vol. 46(3). — P. 364-372.
Copyright (c) 2016 HYPERTENSION
This work is licensed under a Creative Commons Attribution 4.0 International License.
© Publishing House Zaslavsky, 1997-2018